Treatment of luminal HER2-negative breast cancer: opinion of experts
The discussion, dedicated to the treatment of luminal HER2-negative breast cancer stages II and III, was attended by doctors from St. Petersburg – Maria Leonidovna Makarkina, M.D., oncologist of the outpatient department of the N. P. Napalkov Cancer Center, and Elizaveta Vladimirovna Artemyeva, onco...
Saved in:
| Main Authors: | E. V. Artemeva, M. L. Makarkina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2024-06-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/1257 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: N. A. Kozyavin, et al.
Published: (2018-08-01) -
Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01) -
Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
by: Isah Adamu Danbala, et al.
Published: (2025-06-01) -
Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
by: Abhira Deb, et al.
Published: (2025-01-01) -
A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer
by: Xiangjun Li, et al.
Published: (2025-07-01)